2027 MIND Prize supports early-to-mid-career investigators pursuing bold, hypothesis-driven neuroscience research to improve prediction, prevention, and treatment of neurodegenerative diseases.
Funder: Pershing Square Philanthropies
Due Dates (Anticipated): September 2027 (LOI deadline)
Funding Amounts: $750,000 over three years ($250,000 annually); generally at least six prizes annually
Summary: Supports early-to-mid-career investigators pursuing bold, hypothesis-driven neuroscience research, especially on Alzheimer’s disease and dementias.
Key Information: Applicants need a U.S. nonprofit research appointment and one to eight years of independent research experience.
The MIND Prize—Maximizing Innovation in Neuroscience Discovery—is The Pershing Square Foundation’s brain initiative supporting research to improve the prediction, prevention, and treatment of neurodegenerative diseases. It funds early-to-mid-career investigators pursuing scientifically sound, high-risk ideas that may be too speculative for traditional funding. Priority goes to hypothesis-driven work advancing understanding of brain biology and disease mechanisms, particularly Alzheimer’s disease and dementias.
Research may span neurobiology, brain imaging and mapping, machine learning, drug delivery, and synthetic biology. Projects can develop tools or technologies when these test a clearly defined biological hypothesis. Screening cannot be the sole focus. Clinical components are permitted, but clinical trial- or medical device-focused projects are outside scope. Standalone technology, platform-building, large-scale screening, and clinical testing projects are generally uncompetitive without a compelling biological question.